2025-10-30T15:05:29-05:00 2024-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2024-01-01 133870223 INTERNATIONAL AIDS VACCINE INITIATIVE INC INTE 2128471111 125 BROAD STREET 9TH FL NEW YORK NY 10004 BRANDON SAFT CFO 2128471111 2025-10-30 1 0 RICHARD J LOCASTRO CPA P00288314 3019519090 2024 2025-03-06 01:10:19Z IAVI MARK B FEINBERG 125 BROAD STREET 9TH FL NEW YORK NY 10004 139202371 0 X WWW.IAVI.ORG X 1996 DE TRANSLATE SCIENTIFIC DISCOVERIES INTO AFFORDABLE, GLOBALLY ACCESSIBLE PUBLIC HEALTH SOLUTIONS 14 13 260 13 0 0 124587673 126009254 2297276 2511798 2762423 2295284 31028 365139 129678400 131181475 31255891 33692633 0 0 48531593 50838786 0 0 223595 53108753 58512176 132896237 143043595 -3217837 -11862120 124233943 129852638 60310191 78459588 63923752 51393050 X A NONPROFIT SCIENTIFIC RESEARCH ORGANIZATION THAT DEVELOPS VACCINES AND ANTIBODIES FOR HIV, TUBERCULOSIS, AND EMERGING INFECTIOUS DISEASES. 0 0 127097658 33692633 2511798 RESEARCH AND DEVELOPMENT: THROUGH SCIENTIFIC AND CLINICAL RESEARCH IN AFRICA, INDIA, EUROPE, AND THE U.S., IAVI DEVELOPS VACCINES AND ANTIBODIES IN AND FOR THE DEVELOPING WORLD AND SEEKS TO ACCELERATE THEIR INTRODUCTION IN LOW-INCOME COUNTRIES. IAVI ADVANCES SCIENTIFIC DISCOVERY AND DEVELOPMENT BY FOSTERING UNIQUE COLLABORATIONS AMONG ACADEMIA, INDUSTRY, LOCAL COMMUNITIES, GOVERNMENTS, AND FUNDERS TO EXPLORE NEW AND BETTER WAYS TO ADDRESS PUBLIC HEALTH THREATS THAT DISPROPORTIONATELY AFFECT PEOPLE LIVING IN POVERTY. VACCINE AND ANTIBODY CANDIDATES ARE PUT THROUGH A RIGOROUS PROCESS OF CLINICAL EVALUATION AMONG KEY POPULATIONS TO ESTABLISH THEIR SAFETY AND EFFICACY, AN EFFORT THAT ENABLES IAVI TO STRENGTHEN THE HEALTHCARE INFRASTRUCTURE AND SCIENTIFIC CAPACITY OF COUNTRIES WHERE OUR CLINICAL PARTNERS OPERATE. TO DATE, IAVI AND ITS PARTNERS HAVE ADVANCED DOZENS OF HIV VACCINE CANDIDATES INTO EARLY-STAGE CLINICAL TRIALS, INCLUDING A VACCINE CANDIDATE THAT HAS YIELDED PROMISING EARLY RESULTS AND IS PART OF AN EXCITING NEW APPROACH TO HIV VACCINE DESIGN. OTHER NOTABLE ACHIEVEMENTS INCLUDE THE FIRST HIV VACCINE TRIALS IN SUB-SAHARAN COUNTRIES, WHERE HIV BURDEN IS GREATEST, AND THE FIRST TRIAL OF AN MRNA HIV VACCINE CANDIDATE IN AFRICA. IAVI HAS CONDUCTED MORE THAN 50 EPIDEMIOLOGICAL STUDIES AND PROVIDED VOLUNTARY HIV TESTING, COUNSELING SERVICES, AND HEALTH CARE REFERRALS TO MORE THAN 870,000 INDIVIDUALS IN AFRICA. IAVI ALSO SUPPORTS PRECLINICAL DEVELOPMENT AND CLINICAL TESTING OF VACCINE CANDIDATES FOR OTHER DISEASES, INCLUDING TUBERCULOSIS, LASSA FEVER, MARBURG, AND EBOLA SUDAN, AS WELL AS ANTIBODY CANDIDATES FOR DISEASE PREVENTION AND TREATMENT. IAVI CONDUCTS TRIALS WITH THE HIGHEST SCIENTIFIC AND ETHICAL STANDARDS TO PROTECT THE RIGHTS, WELL-BEING, AND DIGNITY OF TRIAL VOLUNTEERS. IAVI HAS ALSO LAUNCHED RESEARCH CONSORTIA TO ADDRESS MAJOR SCIENTIFIC PROBLEMS OF BIOMEDICAL PRODUCT DEVELOPMENT. A SIGNIFICANT PORTION OF RESEARCH IAVI SUPPORTS IS CONDUCTED IN LOW-INCOME COUNTRIES WHERE THE NEED FOR INFECTIOUS DISEASE PREVENTION IS GREATEST. IAVI ALSO SUPPORTS EXTERNAL RESEARCHERS BY PROVIDING TECHNICAL AND SCIENTIFIC EXPERTISE TO ACCELERATE THE DEVELOPMENT OF THEIR OWN PRODUCTS. 127097658 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 1 0 0 1 95 0 1 260 1 0 1 IN SF UK 0 0 0 0 0 0 0 0 0 0 X 14 13 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 X X X LAKHERAM SUKHDEO 2127635462 125 BROAD STREET 9TH FL NEW YORK NY 10004 MARK B FEINBERG PRESIDENT/CEO 35.00 X X 718500 0 65874 ERIC PAUL GOOSBY BOARD CHAIR 2.00 X X 0 0 0 ROBERT GOLDBERG BOARD TREASURER 2.00 X X 0 0 0 LINDA-GAIL BECKER BOARD MEMBER 1.00 X 0 0 0 DAVID BLUMBERG BOARD MEMBER 1.00 X 0 0 0 JIM CONNOLLY BOARD MEMBER 1.00 X 0 0 0 MARK DYBUL BOARD MEMBER 1.00 X 0 0 0 WAFAA EL-SADR BOARD MEMBER 1.00 X 0 0 0 ALEXIS M PINTO BOARD MEMBER 1.00 X 0 0 0 JOHN W SHIVER BOARD MEMBER 1.00 X 0 0 0 SUSAN SILBERMANN BOARD MEMBER 1.00 X 0 0 0 ANNE MARTIN SIMONDS BOARD MEMBER 1.00 X 0 0 0 RAJEEV VENKAYYA BOARD MEMBER 1.00 X 0 0 0 MARIJKE WIJNROKS BOARD MEMBER 1.00 X 0 0 0 ANA CESPEDES MONTOYA CHIEF OPERATING OFFICER 35.00 X 552506 0 61628 MARIO GAGLIANO CHIEF PEOPLE OFFICER, VP OF HR 35.00 X 364310 0 80875 MIN DING GENERAL COUNSEL/BOARD SECRETARY 35.00 X 368570 0 72448 LOUIS D SCHWARTZ ASST. SEC., CHIEF FIN. & ADMIN OFF. 35.00 X 353545 0 68561 BRANDON SAFT DEPUTY CHIEF FINANCIAL OFFICER 35.00 X 255811 0 22267 SWATI GUPTA VP, HEAD OF EID AND EPIDEMIOLOGY 35.00 X 402341 0 68395 CHRISTOPHER PARKS ASS. VP, VIRAL VACC. & HEAD OF DDL 35.00 X 380753 0 71334 DAGNA LAUFER VP AND HEAD OF CLINICAL DEVELOPMENT 35.00 X 402844 0 38942 MARION GRUBER VP, PUBLIC HEALTH & REG. SCIENCE 35.00 X 383236 0 38841 SANGEETHA SAGAR VICE PRESIDENT, PDC 35.00 X 384858 0 34985 4567274 0 624150 165 0 1 0 EMMES CORPORATION 401 N WASHINGTON ST STE 700 ROCKVILLE MD 20850 CLINICAL RESEARCH STUDIES 1294397 ITR LABORATORIES CANADA INC 19601 CLARK GRAHAM BAIE DURFE QC CA H9X 3TI REG. AFFAIRS/PRE-CLINICAL CONS. 752190 WHC 31 PRINCESS OF WALES TERR PARKTOWN JOBURG, 2193 SF PROGRAM CONSULTANT 551389 AMPLIFYBIO 1425 PLAIN CITY-GEORGESVILLE RD WEST JEFFERSON OH 43162 REG. AFFAIRS/PRE-CLINICAL CONS. 426100 AUSTRALIAN BIOLOGICS PTY LTD PO BOX 253 VERMONT VICTORIA AS 3133 LEGAL SERVICES 376692 15 114881 65643855 60250518 126009254 CONTRACT SERVICE FEES 900099 1896798 1896798 RESEARCH & DEVELOPMENT 900099 615000 615000 2511798 2365037 2365037 7951143 8020896 -69753 -69753 -69753 DATA DEF. BUILD OUT 900099 150000 150000 PROPERTY REASSESS. 900099 128245 128245 MISCELLANEOUS 900099 86894 86894 365139 131181475 2511798 0 2660423 7951405 7951405 25741228 25741228 2984897 182329 2802568 37714276 28906033 8788918 19325 3378540 3378540 3942069 3877629 64440 2819004 2819004 545941 146199 399742 201935 201935 180000 180000 75428 75428 1068244 106489 961755 1104638 737670 366968 2110758 1625717 485041 4454015 4017180 436835 2187165 1853259 329461 4445 581763 535859 45904 465337 329698 135639 RESEARCH&CLINICAL SVCS 39380479 38907146 473333 LAB SUPPLIES/EQUIPMENT 4779891 4779891 EQUIPMENT MAINT. 824274 801517 22757 OFFICE FURNITURE 288378 288378 263930 112487 131618 19825 143043595 127097658 15722342 223595 34403229 18632887 46434558 43074450 279535 219130 146763 241274 48104225 47263032 927381 841193 33407409 36526217 8635068 30317487 124233943 129852638 9420265 7911112 11781746 9292944 28968880 31126467 10139300 30129065 60310191 78459588 X 32056013 27604225 31867739 23788825 63923752 51393050 124233943 129852638 X -11862120 1822 -670404 X 0 1 X 1 1 1 X 88668597 124414676 143987755 124587673 126009254 607667955 88668597 124414676 143987755 124587673 126009254 607667955 163150479 444517476 741488 613689 751530 3256766 2365037 7728510 226173 171107 403411 31028 365139 1196858 616593323 16552531 0.72090 0.73460 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2020 AMOUNT: $ 114,697. 2021 AMOUNT: $ 103,555. 2022 AMOUNT: $ 403,411. 2023 AMOUNT: $ 31,028. 2024 AMOUNT: $ 86,894. DATA DEF BUILD OUT - 2024 AMOUNT: $ 150,000. PROPERTY REASSESS - 2024 AMOUNT: $ 128,245. ASSET TRANSFER CREDIT - 2020 AMOUNT: $ 47,875. LOAN FORGIVENESS - 2020 AMOUNT: $ 63,601. 2021 AMOUNT: $ 67,552. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 180000 180000 142788167 142968167 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 247500 247500 225000 180000 900000 250000 250000 250000 250000 1000000 1500000 20305061 20003216 301845 27799164 27259816 539348 841193 SECURITY DEPOSITS 519049 LOAN & EXCHANGE 6867 RIGHT-OF-USE ASSETS 29791571 30317487 OPERATING LEASE LIABILITIES 29628865 DEFERRED COMPENSATION PAYABLE 500200 30129065 132454972 1822 1545738 1547560 130907412 75428 198635 274063 131181475 143484259 12276076 12276076 131208183 75428 11759984 11835412 143043595 PART XI, LINE 2D - OTHER ADJUSTMENTS: REVENUE OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE 57,225. INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. REVENUE OF IAVI INDIA, INCLUDED IN CONSOLIDATED AUDIT 364,050. REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. REVENUE OF IAVI-SA, INCLUDED IN CONSOLIDATED AUDIT 280,919. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. REVENUE OF IAVI-AFRICA, INCLUDED IN CONSOLIDATED AUDIT 843,544. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. PART XI, LINE 4B - OTHER ADJUSTMENTS: INTER-COMPANY REVENUE, ELIMINATED IN CONSOLIDATED AUDIT 198,635. REPORT BUT INCLUDED IN IAVI, INC. FORM 990. PART XII, LINE 2D - OTHER ADJUSTMENTS: EXPENSES OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE 2,693,433. INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. EXPENSES OF IAVI INDIA, INCLUDED IN CONSOLIDATED AUDIT 221,619. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. EXPENSES OF IAVI-SA, INCLUDED IN CONSOLIDATED AUDIT 4,125,216. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. EXPENSES OF IAVI-AFRICA, INCLUDED IN CONSOLIDATED AUDIT 5,235,808. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. PART XII, LINE 4B - OTHER ADJUSTMENTS: INTER-COMPANY GRANT EXPENSES, ELIMINATED IN CONSOLIDATED 11,759,984. AUDIT REPORT BUT INCLUDED IN IAVI, INC. FORM 990. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 5398035 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 331974 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 19840392 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 170827 NORTH AMERICA 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 25110856 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 38948 EUROPE (INCLUDING ICELAND & GREENLAND) 1 11 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 9867346 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 1679158 SOUTH AMERICA 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 21081 SOUTH ASIA 1 25 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 1410343 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 1104127 1 11 1 25 2 36 62437536 2535551 64973087 MIDDLE EAST AND NORTH AFRICA RESEARCH & DEVELOPMENT 170827 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY 684059 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH & DEVELOPMENT 168170 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH & DEVELOPMENT 1078090 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH & DEVELOPMENT 243716 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH & DEVELOPMENT 40299 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY 2237763 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH & DEVELOPMENT 17250 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH & DEVELOPMENT 523573 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH & DEVELOPMENT 260064 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH & DEVELOPMENT 31941 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH & DEVELOPMENT 113110 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 258173 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 6391 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 60448 WIRE TRANSFER 0 SOUTH ASIA RESEARCH & DEVELOPMENT 6962 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1464016 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 97436 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 639452 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1165709 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 58769 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 963677 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1132927 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 184144 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 791683 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 857271 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 123684 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 230000 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 522500 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1370507 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 40709 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 155707 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 164952 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 224850 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 228166 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 100648 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 4145586 WIRE TRANSFER 0 SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 5178000 WIRE TRANSFER 0 30 8 1 0 0 0 0 0 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT AND DONOR TERMS WHICH INCLUDES REVIEW OF 2 CFR 200 AND THE FAR. ROUTINE COMPLIANCE AND SUBSTANTIVE AUDITS ARE PERFORMED BY A COMPLIANCE OFFICER LOCATED IN EAST AFRICA. ROUTINE INTERNAL CONTROL QUESTIONNAIRES, AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES TAKES PLACE ON A REGULAR BASIS. 1 THE SCRIPPS RESEARCH INSTITUTE - OSP 10550 NORTH TORREY PINES ROAD LA JOLLA CA 92037 330435954 501(C)(3) 2739912 0 RESEARCH & DEVELOPMENT TEXAS BIOMEDICAL RESEARCH INSTITUTE 8715 W MILITARY DR SAN ANTONIO TX 78227 741109630 501(C)(3) 61388 0 RESEARCH & DEVELOPMENT RESILIENCE GOVERNMENT SERVICES INC 13200 NW NANO COURT ALACHUA FL 32615 593615370 520971 0 RESEARCH & DEVELOPMENT LA JOLLA INSTITUTE FOR ALLERGY & IMMUNOLOGY 9420 ATHENA CIRCLE LA JOLLA CA 92037 330328688 501(C)(3) 277125 0 RESEARCH & DEVELOPMENT EMORY UNIVERSITY 1599 CLIFTON ROAD ATLANTA GA 30332 580566256 501(C)(3) 352302 0 RESEARCH & DEVELOPMENT UNIVERSITY OF NORTH CAROLINE CHAPEL HILL 104 AIRPORT DRIVE SUITE 2200 CHAPEL HILL NC 27599 566001393 501(C)(3) 138380 0 RESEARCH & DEVELOPMENT THE MITCHELL GROUP INC (TMG) 1816 11TH STREET NW WASHINGTON DC 20001 521467119 168266 0 RESEARCH & DEVELOPMENT BOSTON UNIVERSITY TRUSTEES OF BU 881 COMMONWEALTH AVENUE BOSTON MA 02115 042103547 501(C)(3) 936607 0 RESEARCH & DEVELOPMENT LSB RESEARCH GROUP LLC 113 N ROBINSON STREET MILES TX 76861 752698571 47500 0 RESEARCH & DEVELOPMENT SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 910961784 501(C)(3) 309599 0 RESEARCH & DEVELOPMENT NORTHWESTERN UNIVERSITY 750 N LAKE SHORE DRIVE 7TH FLOOR CHICAGO IL 60611 362167817 501(C)(3) 200000 0 RESEARCH & DEVELOPMENT SUNY GRADUATE SCHOOL 110 STATE STREE ALBANY NY 12236 146013200 501(C)(3) 39028 0 RESEARCH & DEVELOPMENT THE POPULATION COUNCIL INC ONE DAG HAMMARSKJOLD PLAZA 3RD FLOOR NEW YORK NY 10017 131687001 36925 0 RESEARCH & DEVELOPMENT THE BRIGHAM AND WOMEN'S HOPITAL INC 75 FRANCIS STREET BOSTON MA 02115 042312909 501(C)(3) 115765 0 RESEARCH & DEVELOPMENT FRED HUTCHINSON CANCER RESEACH CENTER 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 98109 237156071 501(C)(3) 19309 0 RESEARCH & DEVELOPMENT GEORGE WASHINGTON UNIVERSITY 45155 RESEARCH PLACE - STE 160 ASHBURN VA 20147 530196584 501(C)(3) 12122 0 RESEARCH & DEVELOPMENT APPLIED BIOMEDICAL SCIENCE INSTITUTE APPLIED BIOMEDICAL SCIENCE INSTITUTE SAN DIEGO CA 92127 825056708 501(C)(3) 86085 0 RESEARCH & DEVELOPMENT PATH 445 MASSACHUSETTS AVENUE NW STE 1000 WASHINGTON DC 20001 911157127 501(C)(3) 19000 0 RESEARCH & DEVELOPMENT MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 232251 0 RESEARCH & DEVELOPMENT RESILIENCE US INC 9310 ATHENA CIRCLE SUITE 130 LA JOLLA CA 92037 853165520 127099 0 RESEARCH & DEVELOPMENT JOHNS HOPKINS UNIVERSITY 3910 KESWICK ROAD N4327-B BALTIMORE MD 21201 520595110 501(C)(3) 51745 0 RESEARCH & DEVELOPMENT FHI CLINICAL INC 359 BLACKWELL STREET SUITE 200 DURHAM NC 27701 237413005 501(C)(3) 1375993 0 RESEARCH & DEVELOPMENT GENSCRIPT USA INCORPORATED 860 CENTENNIAL AVENUE PISCATAWAY NJ 08854 364654831 77610 0 RESEARCH & DEVELOPMENT ABCAM INC 152 GROVE STREET SUITE 1100 WALTHAM MA 02241 061682607 6423 0 RESEARCH & DEVELOPMENT 17 7 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT AND DONOR TERMS WHICH INCLUDES REVIEW OF 2 CFR 200 AND THE FAR. REVIEW OF 2 CFR 200 AUDITS AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES TAKES PLACE ON A REGULAR BASIS. X X X X 0 0 0 0 0 0 0 1 0 MARK B FEINBERG PRESIDENT/CEO 594776 0 62382 0 61342 0 65182 0 692 0 784374 0 0 0 ANA CESPEDES MONTOYA CHIEF OPERATING OFFICER 456945 0 44647 0 50914 0 38250 0 23378 0 614134 0 0 0 SWATI GUPTA VP, HEAD OF EID AND EPIDEMIOLOGY 336711 0 33216 0 32414 0 38250 0 30145 0 470736 0 0 0 CHRISTOPHER PARKS ASS. VP, VIRAL VACC. & HEAD OF DDL 315208 0 30809 0 34736 0 38250 0 33084 0 452087 0 0 0 MARIO GAGLIANO CHIEF PEOPLE OFFICER, VP OF HR 336672 0 24644 0 2994 0 31625 0 49250 0 445185 0 0 0 DAGNA LAUFER VP AND HEAD OF CLINICAL DEVELOPMENT 339864 0 24950 0 38030 0 38250 0 692 0 441786 0 0 0 MIN DING GENERAL COUNSEL/BOARD SECRETARY 306375 0 29201 0 32994 0 37667 0 34781 0 441018 0 0 0 LOUIS D SCHWARTZ ASST. SEC., CHIEF FIN. & ADMIN OFF. 293701 0 25688 0 34156 0 33780 0 34781 0 422106 0 0 0 MARION GRUBER VP, PUBLIC HEALTH & REG. SCIENCE 330252 0 30712 0 22272 0 38841 0 0 0 422077 0 0 0 SANGEETHA SAGAR VICE PRESIDENT, PDC 352921 0 25726 0 6211 0 34985 0 0 0 419843 0 0 0 BRANDON SAFT DEPUTY CHIEF FINANCIAL OFFICER 217613 0 10000 0 28198 0 12808 0 9459 0 278078 0 0 0 PART I, LINE 7 MERIT-BASED BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). DESMOND TUTU HIV FOUNDATION AN IAVI BOARD MEMBER IS THE DEPUTY DIRECTOR AND COO OF THE ENTITY. 58769 IAVI HAS A SUB-AWARD AGREEMENT WITH DESMOND TUTU INSTITUTE FOR HIV RESEARCH FOUNDATION. 0 FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS REVIEWED IN DETAIL BY THE CONTROLLER AND CFO AGAINST THE AUDITED FINANCIAL STATEMENTS BEFORE FILED WITH THE IRS. PLEASE NOTE THAT THE FINANCIAL STATEMENTS ARE FIRST REVIEWED AND APPROVED BY THE AUDIT AND FINANCE COMMITTEE AND SHARED WITH THE FULL BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C IAVI HAS A CONFLICT OF INTEREST POLICY WHICH APPLIES TO ALL DIRECTORS, OFFICERS, KEY PERSONS, EMPLOYEES, CONSULTANTS AND ADVISORY COMMITTEE MEMBERS. THE POLICY REQUIRES THAT ALL DIRECTORS, OFFICERS, KEY PERSONS, EMPLOYEES AND ADVISORY COMMITTEE MEMBERS FILE AN ANNUAL DISCLOSURE FORM, INDICATING WHETHER THERE ARE ANY POSSIBLE OR ACTUAL CONFLICTS AS DEFINED UNDER THE POLICY. IN ADDITION, ALL ARE REQUIRED TO DISCLOSE ANY POSSIBLE OR ACTUAL CONFLICTS ON AN ONGOING BASIS. ANNUAL DISCLOSURE FORMS, AS WELL OTHER CONFLICT OF INTEREST DISCLOSURES THAT ARISE DURING THE YEAR, ARE FILED WITH AND REVIEWED BY THE GENERAL COUNSEL'S OFFICE. IN ADDITION, THE AUDIT & FINANCE COMMITTEE REVIEWS CONFLICT OF INTEREST DISCLOSURES THAT INVOLVE A DIRECTOR, OFFICER, OR KEY PERSON. IN EACH CASE, THE REVIEW ENSURES THAT ANY CONFLICT OF INTEREST OR POSSIBLE CONFLICT OF INTEREST IS PROPERLY ADDRESSED, MITIGATED, AND/OR MANAGED. CONFLICT OF INTEREST DISCLOSURES ARE SUMMARIZED AND PROVIDED TO THE CHAIR OF THE AUDIT & FINANCE COMMITTEE FOR REVIEW BY THE AUDIT & FINANCE COMMITTEE. IF ANY CONFLICT OF INTEREST OR POSSIBLE CONFLICT OF INTEREST DISCLOSURE INVOLVES THE CHAIR OF THE AUDIT & FINANCE COMMITTEE, THE COMMITTEE MEETS WITHOUT THE CHAIR. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE OF THE BOARD CAN PERIODICALLY COMMISSION A COMPENSATION SURVEY OF THE CEO'S COMPENSATION PACKAGE. WHEN DONE THIS SURVEY COMPARES COMPENSATION PACKAGES OF CEOS OF ORGANIZATIONS THAT ARE COMPARABLE TO IAVI. THEN THE COMMITTEE REVIEWS THE RESULTS AND MAKES RECOMMENDATIONS, DISCUSSES THIS WITH THE BOARD BEFORE PROVIDING SPECIFIC GUIDANCE AND APPROVAL TO IAVI'S MANAGEMENT. THE COMPENSATION COMMITTEE DETERMINES THE APPROPRIATE PACKAGE FOR THE CEO AND THE BOARD CHAIR SHARES THIS INFORMATION WITH HUMAN RESOURCES FOR IMPLEMENTATION. IAVI MAKES USE OF DATA FROM A SPECIALIZED COMPENSATION FIRM TO CONDUCT THE SURVEY AND PROVIDE RECOMMENDATION TO THE COMPENSATION COMMITTEE. THE DELIBERATIONS OF THE COMPENSATION COMMITTEE OF THE BOARD ARE DOCUMENTED IN THE COMPENSATION COMMITTEE MINUTES FOR EACH MEETING OF THE MEMBERS. ALSO, THE SAME IS CAPTURED IN THE BOARD MINUTES AS REPORTED OUT BY THE COMPENSATION COMMITTEE CHAIR FOR BOARD DISCUSSIONS AND APPROVAL. THE LAST COMPENSATION REVIEW TOOK PLACE IN DECEMBER 2024. THE COMMITTEE HAD NOT REQUESTED A COMPENSATION SURVEY SPECFIC TO CEO PAY THIS YEAR SO MANAGEMENT REFERENCED EXTENRAL DATA SOURCES TO DETERMINE THE COMPETITIVE LANDSCAPE AND DEVELOP ANNUAL INCREASE RECOMMENDATIONS FOR THE CEO AND OTHER KEY PERSONNEL. THE COMMITTEE REVIEWS THE RESULTS AND RECOMMENDATIONS FROM THESE SOURCES AND PROVIDES MANAGEMENT WITH SPECIFIC GUIDANCE IN ADDRESSING ANY DISPARITIES. USING BENCHMARK JOB CLASSIFICATIONS, IAVI PURCHASES EXTERNAL SALARY SURVEY DATA, AND USES THIS DATA ACROSS ALL ITS OFFICES TO DETERMINE THE COMPETITIVENESS OF ITS COMPENSATION PROGRAMS AND TO ENABLE THE ORGANIZATION TO CONTINUE TO ATTRACT AND RETAIN THE RIGHT TALENT IN THESE VARIOUS MARKETS. IN MOST CASES THE LOCAL LABOR MARKET IS CONSIDERED AND FOR CERTAIN POSITIONS, REGIONAL MARKETS MUST BE TARGETED. SALARY RECOMMENDATIONS AND EXTERNAL DATA TRENDS MAY BE REVIEWED WITH THE COMPENSATION COMMITTEE OF THE BOARD, WHICH GIVES MANAGEMENT OVERALL GUIDANCE ON COMPENSATION DIRECTION. BASED ON RECOMMENDATIONS AND GUIDANCE OF THE COMPENSATION COMMITTEE, THE EXECUTIVE OFFICE AND HUMAN RESOURCES COMMUNICATE CHANGES TO ANY AFFECTED EMPLOYEES. ANY COMPENSATION CHANGES ARE DETERMINED BASED ON EXTERNAL COMPETIVENESS, RELATIVE INTERNAL VALUE, INDIVIDUAL PERFORMANCE, TEAM DYNAMIC, AND IAVI'S ABILITY TO PAY. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE ON ITS WEBSITE. FORM 990, PART XI, LINE 9: FOREIGN EXCHANGE GAIN -716,289. CURRENCY TRANSLATION 45,885. IAVI LAB LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 262031769 LAB RESEARCH DE 0 0 IAVI INC IAVI GLOBAL HEALTH IMPACT LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 FACILITATE PRODUCT DEVELOPMENT AND/OR COMMERCIALIZATION DE 0 0 IAVI INC STICHTING IAVI VAN DIEMENSTRAAT 48 1013 NH AMSTERDAM NL RESEARCH SUPPORT NL N/A N/A IAVI INC 1 IAVI INDIA 4 FACTORY ROAD GROUND FLOOR ANSARI NAGAR WEST NEW DELHI-110029 IN RESEARCH SUPPORT IN N/A N/A IAVI INC 1 IAVI SOUTH AFRICA NPC (IAVI-SA) BLACK RIVER PARK 2 FIR ST OBSERVA CAPETOWN SF RESEARCH SUPPORT SF N/A N/A IAVI INC 1 IAVI AFRICA LIMITED 11TH FL MUTHANGARI DR PO BOX 340 NAIROBI KE RESEARCH SUPPORT KE N/A N/A IAVI INC 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 STICHTING IAVI B 2237763 ACTUAL STICHTING IAVI C 52809 ACTUAL IAVI SOUTH AFRICA NPC B 4145586 ACTUAL IAVI-INDIA C 62072 ACTUAL IAVI AFRICA LIMITED B 5178000 ACTUAL